Search

Displaying results 6711 - 6720 of 10000 in total
  1. Drug

    VB2-011

    go.drugbank.com/drugs/DB05411
    Experimental

    VB2-011 is an antibody developed as an anti-cancer treatment. According to some preclinical studies, it has a potential to inhibit tumour growth in various cancers including lymphoma and melanoma. … This drug includes the parent IgM (H11 IgM) and a recombinant IgG version (H11 IgG).

  2. Drug

    Sparfosic acid

    go.drugbank.com/drugs/DB03459
    Experimental

    Sparfosic acid is a solid. This compound belongs to the n-acyl-alpha amino acids. These are compounds containing an alpha amino acid which bears an acyl group at the terminal nitrogen atom.

  3. Drug

    Taberminogene vadenovec

    go.drugbank.com/drugs/DB05011
    Experimental

    Taberminogene vadenovec (EG004) is a novel product consisting of a local delivery device and a gene-based medicine, being developed to prevent the blocking of veins and arteries that frequently occurs … that their blood can be regularly filtered using a dialysis machine.

  4. Drug

    Tunicamycin

    go.drugbank.com/drugs/DB13172
    Experimental

    Tunicamycin blocks N-linked glycosylation (N-glycans) resulting in cell cycle arrest at the G1 phase in human cells. It is used as an experimental tool to induce unfolded protein response. … Tunicamycin is a mixture of homologous nucleoside antibiotics that inhibits the UDP-HexNAc: polyprenol-P HexNAc-1-P family of enzymes.

  5. Drug

    Zandatrigine

    go.drugbank.com/drugs/DB19051
    Investigational

    Zandatrigine is under investigation in clinical trial NCT05226780 (Extension Study to Evaluate How Safe and Tolerable NBI-921352 Is as an Adjunctive Therapy for Participants With SCN8A-DEE).

  6. Drug

    Arsanilic acid

    go.drugbank.com/drugs/DB03006
    ExperimentalVet approved

    An arsenical which has been used as a feed additive for enteric conditions in pigs and poultry. It causes blindness and is ototoxic and nephrotoxic in animals. [PubChem]

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    EHT899

    go.drugbank.com/drugs/DB05108
    Experimental

    EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. … It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load.

  8. Drug

    Bisegliptin

    go.drugbank.com/drugs/DB06127
    Investigational

    Bisegliptin is a compound for the treatment of type 2 diabetes. … It is an orally active, dipeptidyl peptidase-IV (DPPIV) inhibitor which lowers blood glucose levels by blocking the degradation of the hormone GLP-1 thereby stimulating glucose-dependent insulin secretion

  9. Drug

    Burosumab

    go.drugbank.com/drugs/DB14012
    ApprovedInvestigational

    XLH is a serious disease which affects about 3,000 children and 12,000 adults in the United States. … It causes impaired bone growth and development in children and adolescents and issues with bone mineralization throughout a patient’s life [L2346].

  10. Drug

    Lurbinectedin

    go.drugbank.com/drugs/DB12674
    ApprovedInvestigational

    the substitution of the tetrahydroisoquinoline with a tetrahydro β‐carboline that results in increased antitumour activity of lurbinectedin as compared to its predecessor. … Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma,[A214325] chronic lymphocytic leukemia (CLL),[A214328] breast cancer,